Karyopharm Therapeutics INC Form 4 insider transactions

Stuart Poulton, EVP, Chief Development Officer of Karyopharm Therapeutics Inc., sold 189 shares of common stock on July 28, 2026 for $7.10 per share.

Karyopharm Therapeutics Inc. reports the grant of restricted stock units to Director Deepika Pakianathan.

Karyopharm Therapeutics Inc. director Chen Schor was awarded 15,508 restricted stock units under the company's 2022 Equity Incentive Plan.

Karyopharm Therapeutics Inc. reports the grant of 15,508 restricted stock units to Director Zhen Su.

Karyopharm Therapeutics Inc. reports an award of restricted stock units to Director Garen Bohlin, with vesting scheduled for May 21, 2027.

Barry E. Greene, a Director at Karyopharm Therapeutics Inc., has reported the acquisition of 15,508 restricted stock units (RSUs) under the company's 2022 Equity Incentive Plan.

EVP & Chief Commercial Officer Sohanya Cheng acquired 947 shares via PSU vesting and sold 324 shares to cover tax obligations.

CEO Richard Paulson acquired 4,920 shares via performance-based restricted stock units and sold 2,203 shares to cover tax obligations.

Karyopharm Therapeutics EVP & Chief Medical Officer Reshma Rangwala sold 449 shares of common stock on April 21, 2026, for $8.94 per share, as part of a pre-arranged trading plan to cover tax liabilities.

Karyopharm Therapeutics' EVP, Chief Development Officer Stuart Poulton, sold 378 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Karyopharm Therapeutics Inc. CEO Richard Paulson received an award of 81,060 restricted stock units vesting over two years.

Karyopharm Therapeutics' EVP, CFO & Treasurer, Lori Macomber, sold 1,626 shares of common stock at $6.3 per share to cover tax liabilities from restricted stock unit vesting.

Karyopharm Therapeutics' EVP & Chief Commercial Officer, Sohanya Cheng, was granted 32,415 restricted stock units under the company's 2022 Equity Incentive Plan.

Karyopharm Therapeutics' EVP and Chief Medical Officer, Reshma Rangwala, received an award of 32,415 restricted stock units.

Karyopharm Therapeutics Inc.'s EVP, CFO & Treasurer, Lori Macomber, was awarded 32,415 restricted stock units as part of the company's 2022 Equity Incentive Plan.

Karyopharm Therapeutics Inc.'s EVP, CLO & Secretary, Michael Mano, was granted 32,415 restricted stock units vesting over two years.

Karyopharm Therapeutics' EVP, Chief Development Officer, Stuart Poulton, received an award of 32,415 restricted stock units.

Karyopharm Therapeutics' Chief Accounting Officer, Kristin Abate, acquired 92 shares from vested performance-based restricted stock units and subsequently sold 50 shares to cover tax obligations.

Karyopharm Therapeutics' Chief Accounting Officer, Kristin Abate, sold 265 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Karyopharm Therapeutics Inc. awarded 12,799 restricted stock units to Chief Accounting Officer Kristin Abate under its 2022 Equity Incentive Plan.

Karyopharm Therapeutics Inc.'s EVP and Chief Development Officer, Stuart Poulton, was awarded 39,682 restricted stock units vesting in December 2026.

Karyopharm Therapeutics' SVP, General Counsel & Secretary, Michael Mano, was awarded 43,650 restricted stock units vesting in December 2026.

Karyopharm Therapeutics Inc. President and CEO, Richard A. Paulson, was awarded 114,285 restricted stock units under the company's 2022 Equity Incentive Plan.

Karyopharm Therapeutics Inc. EVP & Chief Commercial Officer Sohanya Roshan Cheng was awarded 43,650 restricted stock units, vesting fully on December 31, 2026.

Karyopharm Therapeutics Inc.'s EVP, CFO & Treasurer, Lori Macomber, received an award of 43,650 restricted stock units (RSUs) under the company's 2022 Equity Incentive Plan.

Karyopharm Therapeutics' Chief Accounting Officer, Kristin Abate, sold 362 shares of common stock at a weighted average price of $6.296 to cover tax liabilities from PSU vesting.

Karyopharm Therapeutics CEO Richard Paulson reported the acquisition of shares from vested performance-based restricted stock units and a subsequent tax-related sale.

Karyopharm Therapeutics' SVP, General Counsel & Secretary, Michael Mano, acquired shares from PSU vesting and subsequently sold a portion for tax obligations.

Karyopharm Therapeutics' EVP, Chief Development Officer, Stuart Poulton, reported the vesting of performance-based restricted stock units and a subsequent tax-related sale of common stock.

Karyopharm Therapeutics' EVP & Chief Medical Officer, Reshma Rangwala, acquired shares from performance-based restricted stock unit vesting and subsequently sold a portion to cover tax liabilities.